20888 Per-Anders Abrahamsson: Prostate cancer - to treat or not to treat? Europ. Urology Suppl. 8 (2009), 418-423. 21055 Gerald Andriole/.../Christine Berg: Mortality results from a randomized prostate-cancer screening trial. New England J. Med. 360/13 (2009), 1310-1319. 16263 Michael Barry: Prostate-specific-antigen testing for early diagnosis of prostate cancer. New England J. Med. 3 May 2001, 1373-1377. 21056 Michael Barry: Screening for prostate cancer - the controversy that refuses to die. New England J. Med. 360/13 (2009), 1351-1354. 21520 Luigi Benecchi/.../Domenico Potenzoni: La logica imperfetta (fuzzy inference system Sugeno-type) nella diagnosi del tumore prostatico. Internet 2009, 14p. 21061 Peter Boyle/Otis Brawley: Prostate cancer - current evidence weighs against population screening. CA Cancer J. Clin. ... (2009), 6p. 21295 Otis Brawley: Prostate cancer screening - is this a teachable moment? J. NCI 101/19 (2009), 1295-1297. 21060 Otis Brawley/Donna Ankerst/Ian Thompson: Screening for prostate cancer. CA Cancer J. Clin. ... (2009), 12p. J. Breul/U. Pickl/J. Schaff: Extraprostatic production of prostate specific antigen is under hormonal control. J. Urology January 1997, ... 16268 H. Butz: Bayer cPSA (komplexiertes PSA). Internet ca. 2002, 5p. 16266 H. Carter: A PSA threshold of 4.0 ng/ml for early detection of prostate cancer - the only rational approach for men 50 years old and older. Urology 55 (2000), 796-799. 16267 H. Carter/Daniel Chan/.../E. Metter/Patrick Walsh: Prostate-specific antigen variability in men without prostate cancer - effect of sampling interval on prostate-specific antigen velocity. Urology 45 (1995), 591-596. 16265 William Catalona/Christian Ramos/.../Yan Yan: Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 55 (2000), 791-795. B. Dalkin/F. Ahmann/J. Kopp: Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J. Urology 150 (1993), 1837-1839. 15475 Patrik Finne a.o.: Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. European Urology 41 (2002), 619-627. J. Fowler/M. Condon/F. Terrell: Cancer diagnosis with prostate specific antigen greater than 10 ng./ml. and negative peripheral zone prostate biopsy. J. Urology October 1996, ... 8944 Gerald Hanks/Peter Scardino: Does screening for prostate cancer make sense? Internet, ca. 1995. [Archiv] [= 10170 Gerald Hanks/Peter Scardino: Kontroverse um PSA-Screening auf Prostatakrebs. In 10158 Hoefer, 55-57.] A. Heidenreich a.o.: Influence of ejaculation on serum levels of prostate specific antigen. J. Urology January 1997, ... E. Higashihara a.o.: Significance of serum free prostate specific antigen in screening of prostate cancer. J. Urology December 1996, ... J. Irani a.o.: Serum-to-urinary prostate specific antigen ratio - its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng./ml. J. Urology January 1997, ... 16264 Kazuto Ito/Takumi Yamamoto/.../Kazuhiro Suzuki/Hidetoshi Yamanaka: Natural history of PSA increase with and without prostate cancer. Urology 62 (2003), 64-69. 20923 Gino Kolata: Prostate test found to save few lives. New York Times 18 March 2009, 3p. 19913 Lionel Lim/Kevin Sherin: Screening for prostate cancer in US men. ACPM position statement on preventive practice. Am. J. Prev. Med. 34/2 (2008), 164-170. 20926 Amelie Lutz/.../Sanjiv Gambhir: Cancer screening - a mathematical model relating secreted blood biomarker levels to tumor sizes. PLOS Medicine August 2008, 1287-1297. T. Morgan a.o.: [On falsely positive PSA]. New England J. Med. August 1996, ... Joseph Oesterling/S. Martin/E. Bergstrahl/F. Lowe: The use of prostate- specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269 (1993), 57-60. D. Ornstein a.o.: Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J. Urology January 1997, ... A. Partin a.o.: Combination of PSA, clinical stage and Gleason Score to predict pathological stage: A multi-institutional update 1996. J. Urol. April 1997, ... This is an update to the Partin Predictions, based on 4133 men, of which 1384 were assigned to a validation cohort. They report that the prediction for organ confined disease had a 75% sensitivity and a specificity of 57%. The prediction for postiive lymph nodes had a sensitivity of 78% and a specificity of 66%. J. Presti/R. Hovey/P. Carroll/K. Shinohara: Prospective evaluation of prostate specific antigen and prostate specific antigen density in detection of nonpalpable and stage T1C carcinoma of prostate. J. Urology November 1996, ... A. Prestigiacomo/T. Stamey: A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J. Urology 152 (1994), 1515-1519. A. Prestigiacomo/T. Stamey: Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J. Urology January 1997, ... Richie a.o.: Effect of patient age on early detection of prostate cancer with serum prostate specific antigen and digital rectal examination. Urology 42 (1993), 365-374. Roehrborn a.o.: Variability of repeated prostate-specific antigen measurements within less than 90 days in a well defined patient population. Urology 47 (1996), 55-66. There are wide fluctuations in PSA readings. 21054 Fritz Schröder/.../Anssi Auvinen: Screening and prostate-cancer mortality in a randomized European study. New England J. Med. 360/13 (2009), 1320-1328. 20050 Axel Semjonow/Walter Albrecht: PSA - haben wir dazugelernt? J. Urologie Urogyn. 14 (2007), Sonderheft 1, 6p. Tom Stamey/Nichols: Prostate cancer - clinical applications of a new chemiluminescent assay for detection of ultrasensitive levels of prostate specific antigen. Ca. 1996. 20219 Kristin Swanson/Hana Harpold/Lawrence True: Prostate-specific antigen - a clinical and mathematical conundrum. Am. J. Clin. Pathol. 125 (2006), 331-333. 16419 Kristin Swanson/Lawrence True/J. Murray: On the use of quantitative modeling to help understand prostate-specific antigen dynamics and other medical problems. Am. J. Clin. Pathol. 119/1 (2003), 14-17. 16420 Kristin Swanson/.../James Murray: A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth. Am. J. Pathol. 158/6 (2001), 2195-2199. 19850 Ian Thompson/Donna Ankerst: Prostate-specific antigen in the early detection of prostate cancer. Can. Med. Ass. J. 176/13 (2007), 1853-1858. 21294 H. Welch/Peter Albertsen: Postate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening 1986-2005. J. NCI 101/19 (2009), 1325-1329. S. Woolf: Screening for prostate cancer with prostate-specific antigen. An examination of evidence. New England J. Med. 333 (1995), 1401-1405. 8950 ZZ: What is PSA, and how do we measure it? Internet, ca. 1995. [Archiv] 9354 ZZ: PSA, DRE, PAP, RTPCR, TRUS, and other diagnostic acronyms. Internet 1995. 16624 ZZ: [The PSA era is over, Thomas Stamey says.] Mail September 2004, 2p. 21062 ZZ: Prostate cancer screening has yet to prove its worth, researchers say. Science Daily 3 June 2009, 3p.